Autonomic Nervous System Drugs Practice Questions

Q: Which of the following would increase the levels of acetylcholine in the synaptic cleft?

Inhibition of acetylcholinesterase. ***Inhibition of acetylcholinesterase*** - **Acetylcholinesterase** is the enzyme responsible for breaking down acetylcholine in the synaptic cleft. - By **inhibiting** this enzyme, acetylcholine persists longer in the cleft, leading to increased levels and prolonged effects. *Administration of glucose* - **Glucose** is the primary energy source for cellular function, including neurotransmitter synthesis and release. - While essential for overall neuronal health, directly administering glucose does not specifically increase acetylcholine levels in the synaptic cleft. *Activation of nicotinic receptors* - **Nicotinic receptors** are postsynaptic receptors that bind acetylcholine, causing neuronal depolarization and muscle contraction. - Their activation mediates the effects of acetylcholine but does not influence the amount of acetylcholine present in the synaptic cleft. *Activation of muscarinic receptors* - **Muscarinic receptors** are another class of acetylcholine receptors, often found on target organs of the parasympathetic nervous system. - Like nicotinic receptors, their activation responds to acetylcholine but does not directly increase its concentration in the synaptic cleft.

Q: Drug of choice for myasthenia gravis -

Pyridostigmine. ***Pyridostigmine*** - **Pyridostigmine** is an **acetylcholinesterase inhibitor** that increases the amount of acetylcholine at the neuromuscular junction, improving muscle strength in myasthenia gravis. - It is the **first-line symptomatic treatment** for generalized myasthenia gravis, helping to alleviate muscle weakness and fatigue. *Succinylcholine* - **Succinylcholine** is a **depolarizing neuromuscular blocker** often used in anesthesia to induce paralysis by mimicking acetylcholine. - In myasthenia gravis patients, its effects can be unpredictable and potentially prolonged due to altered acetylcholine receptor sensitivity, making it a poor choice for treatment and dangerous in surgical settings. *D. tubocurare* - **D-tubocurarine** is a **non-depolarizing neuromuscular blocker** that competitively inhibits acetylcholine at the neuromuscular junction, leading to muscle paralysis. - Patients with myasthenia gravis are highly sensitive to non-depolarizing blockers, and even small doses can cause profound and prolonged paralysis, making it contraindicated in their management. *Gallamine* - **Gallamine** is also a **non-depolarizing neuromuscular blocker** that works by antagonizing acetylcholine receptors at the neuromuscular junction. - Similar to D-tubocurarine, it can cause severe and prolonged neuromuscular blockade in patients with myasthenia gravis, making it an inappropriate and dangerous drug for treatment.

Q: Which of the following drugs can cause neuropsychiatric side effects due to its lipophilic nature and ability to cross the blood-brain barrier?

Propranolol. ***Propranolol*** - Propranolol is a **lipophilic (fat-soluble) non-selective beta-blocker** that readily crosses the **blood-brain barrier (BBB)**, leading to significant central nervous system penetration - This CNS penetration results in **neuropsychiatric side effects** including **depression, nightmares, hallucinations, vivid dreams, fatigue, memory impairment, and confusion** - These neuropsychiatric features are more prominent with **lipophilic beta-blockers** (propranolol, metoprolol) compared to hydrophilic ones (atenolol, nadolol) - This makes propranolol a notable example of an **unexpected neuropsychiatric adverse effect** from a cardiovascular drug *Clozapine* - Clozapine is an **atypical antipsychotic** that does cross the BBB (as it must to exert its therapeutic effect on schizophrenia) - However, it is **not lipophilic** in the same manner as propranolol and works through different mechanisms (dopamine D2 and serotonin 5-HT2A antagonism) - While it causes CNS effects like **sedation and seizures**, these are expected effects of a psychiatric medication, not unexpected neuropsychiatric side effects from a non-CNS drug *Clonidine* - Clonidine is a **centrally-acting alpha-2 agonist** that must cross the BBB to exert its therapeutic antihypertensive effect - It causes **sedation and drowsiness** as part of its primary mechanism of action (reducing sympathetic outflow from the CNS) - These are **expected CNS effects** rather than unexpected neuropsychiatric side effects from peripheral drug action *Disulfiram* - Disulfiram is an **aldehyde dehydrogenase inhibitor** used for alcohol dependence treatment - Its primary side effects relate to the **disulfiram-ethanol reaction** (acetaldehyde accumulation causing flushing, nausea, tachycardia) - While it can cause neuropsychiatric effects in some cases, it is **not particularly lipophilic** and this is not its characteristic adverse effect profile

Q: M2 cholinergic receptor is located at

Heart. ***Heart*** - The **M2 muscarinic acetylcholine receptor** is predominantly located in the **heart**, where its activation mediates parasympathetic effects. - Activation of M2 receptors in the heart leads to a **decrease in heart rate** and force of contraction. *Glands* - **Glandular secretions**, such as saliva, tears, and sweat, are primarily mediated by **M3 muscarinic receptors**. - While M2 receptors may have some minor presence, M3 is the dominant subtype for secretory functions. *Lungs* - **Bronchoconstriction** and increased **mucus secretion** in the lungs are primarily mediated by **M3 muscarinic receptors**. - M2 receptors are present, but their role is often considered to be inhibitory to other M3 effects or to modulate neurotransmitter release. *Skeletal muscle* - **Skeletal muscle contraction** is mediated by **nicotinic acetylcholine receptors (Nm)** at the neuromuscular junction. - Muscarinic receptors, including M2, are not directly involved in skeletal muscle contraction.

Q: Non-depolarizing neuromuscular blocker is characterized by

Reversed by neostigmine. ***Reversed by neostigmine*** - **Non-depolarizing neuromuscular blockers** are **competitive antagonists** at the **nicotinic acetylcholine receptors** at the neuromuscular junction. - **Neostigmine** is an **acetylcholinesterase inhibitor** that increases the concentration of acetylcholine in the synaptic cleft, thereby overcoming the competitive blockade. *Non competitive neuromuscular blocker* - Non-depolarizing neuromuscular blockers are, by definition, **competitive antagonists** at the **nicotinic acetylcholine receptors**. - A non-competitive blocker would bind to a different site on the receptor or an allosteric site to produce its effect. *Induces fasciculations* - **Fasciculations** (visible muscle twitching) are characteristic of **depolarizing neuromuscular blockers** like **succinylcholine**, as they initially activate the receptors before causing prolonged depolarization and paralysis. - Non-depolarizing blockers do not typically cause fasciculations because they prevent acetylcholine from binding and activating the receptors. *Persistent stimulator of nicotinic cholinergic receptors* - This describes the mechanism of action of **depolarizing neuromuscular blockers** like **succinylcholine**, which persistently activate the receptor, leading to initial fasciculations followed by sustained depolarization and paralysis. - **Non-depolarizing blockers** act as **antagonists**, preventing activation of the receptors.

Q: Drug used for d-TC reversal is

Neostigmine. ***Neostigmine*** - **Neostigmine** is an **acetylcholinesterase inhibitor** that increases the concentration of **acetylcholine** at the neuromuscular junction, effectively reversing the effects of competitive (d-TC) neuromuscular blockers. - It is commonly administered with an **anticholinergic agent** like atropine or glycopyrrolate to prevent undesired muscarinic side effects. *Diazepam* - **Diazepam** is a **benzodiazepine** primarily used as an **anxiolytic**, sedative, anticonvulsant, and muscle relaxant (central action), not for reversing neuromuscular blockade. - It potentiates the effect of **GABA**, leading to central nervous system depression. *Atropine* - **Atropine** is an **anticholinergic agent** that blocks muscarinic acetylcholine receptors. - While it is often co-administered with neostigmine to counteract its muscarinic side effects (e.g., bradycardia, salivation), it does not directly reverse the neuromuscular blockade caused by d-TC. *Atracurium* - **Atracurium** is an **intermediate-duration, non-depolarizing neuromuscular blocking agent** itself, similar in action to d-tubocurarine (d-TC). - Therefore, it would worsen, rather than reverse, the neuromuscular blockade.

Q: Atropine is substituted by phenylephrine to facilitate fundus examination when?

Mydriasis required without cycloplegia. ***Mydriasis required without cycloplegia*** - Phenylephrine is a **sympathomimetic** drug that causes **mydriasis (pupil dilation)** by stimulating alpha-1 adrenergic receptors in the iris dilator muscle. - Unlike atropine, phenylephrine has no significant effect on the ciliary muscle, thus it causes minimal to no **cycloplegia (paralysis of accommodation)**, which is ideal if only pupillary dilation is needed for fundus examination without affecting the patient's ability to focus. *Cycloplegia and mydriasis both are not required* - If neither mydriasis nor cycloplegia is required, there would be no need to use phenylephrine or atropine, as the goal is to *facilitate* fundus examination, which typically requires dilation. - This option is incorrect because the question implies a situation where a drug is *substituted* for atropine, indicating a specific need. *Mydriasis and cycloplegia both required* - If both mydriasis and cycloplegia are required, atropine would be the more appropriate choice as it is a potent cycloplegic in addition to being a strong mydriatic. - Phenylephrine does not provide sufficient cycloplegia to meet this requirement. *Cycloplegia is required* - Phenylephrine is a **poor cycloplegic**; its primary action is mydriasis. - If cycloplegia is the main requirement (e.g., for **refraction in children**), drugs like atropine or cyclopentolate would be preferred.

Q: The mechanism of action of botulinum toxin A is best described by:

Presynaptic blockade of acetylcholine release. ***Presynaptic blockade of acetylcholine release*** - **Botulinum toxin A** acts by cleaving specific proteins (**SNARE proteins** like SNAP-25, synaptobrevin, and syntaxin) essential for the fusion of **acetylcholine-containing vesicles** with the presynaptic membrane. - This prevents the release of acetylcholine into the **neuromuscular junction**, leading to muscle paralysis. *Slowing of myelinated nerve fiber transmission* - This describes the action of agents that affect **myelin sheaths** (e.g., demyelinating diseases) or ion channels involved in action potential propagation, not the mechanism of botulinum toxin. - Botulinum toxin specifically targets the **synaptic transmission**, not the speed of nerve conduction itself. *Postsynaptic receptor blockade* - This mechanism is seen with drugs like **curare** or **neuromuscular blockers** (e.g., rocuronium, vecuronium), which compete with acetylcholine for binding to **nicotinic acetylcholine receptors** on the muscle endplate. - Botulinum toxin does not affect the postsynaptic receptors directly; its action is entirely presynaptic. *Acetylcholinesterase inhibition* - **Acetylcholinesterase inhibitors** (e.g., neostigmine, pyridostigmine) prevent the breakdown of acetylcholine in the synaptic cleft, increasing its concentration and prolonging its action. - This mechanism would enhance, rather than block, muscle contraction, which is opposite to the effect of botulinum toxin.

Q: Which of the following non-depolarising muscle relaxant is excreted maximally through the kidney?

Gallamine. ***Gallamine*** - **Gallamine** is predominantly cleared by the kidneys, with **80-100% of the unchanged drug** excreted via **renal elimination**. - Its use can be problematic in patients with renal impairment due to the risk of **prolonged paralysis** and **tachycardia**. *Rocuronium* - Rocuronium is primarily eliminated through the **bile** and **liver**, with a small fraction excreted renally. - While some renal excretion occurs, it is not the main pathway, making it a safer option than gallamine in patients with renal dysfunction. *Vecuronium* - Vecuronium undergoes significant **hepatic metabolism** to inactive metabolites, with subsequent biliary and renal excretion. - Its elimination half-life can be extended in patients with **liver disease**, but **renal excretion is minimal** for the parent drug. *Pancuronium* - **Pancuronium** is mainly eliminated by a combination of **hepatic metabolism** and **renal excretion**. - Approximately **40-60%** of the drug is excreted unchanged in the urine, but a substantial portion is metabolized by the liver.

Question 1

Which of the following would increase the levels of acetylcholine in the synaptic cleft?

Accepted Answer

Inhibition of acetylcholinesterase

Answer

Administration of glucose

Answer

Activation of nicotinic receptors

Answer

Activation of muscarinic receptors

Question 2

Drug of choice for myasthenia gravis -

Accepted Answer

Pyridostigmine

Answer

D. tubocurare

Answer

Gallamine

Answer

Succinylcholine

Question 3

Which of the following drugs can cause neuropsychiatric side effects due to its lipophilic nature and ability to cross the blood-brain barrier?

Accepted Answer

Propranolol

Answer

Clozapine

Answer

Clonidine

Answer

Disulfiram

Question 4

M2 cholinergic receptor is located at

Accepted Answer

Heart

Answer

Glands

Answer

Lungs

Answer

Skeletal muscle

Question 5

Non-depolarizing neuromuscular blocker is characterized by

Accepted Answer

Reversed by neostigmine

Answer

Non competitive neuromuscular blocker

Answer

Induces fasciculations

Answer

Persistent stimulator of nicotinic cholinergic receptors

Question 6

Drug used for d-TC reversal is

Accepted Answer

Neostigmine

Answer

Diazepam

Answer

Atropine

Answer

Atracurium

Question 7

To which muscle relaxant are patients with myasthenia gravis (MG) most sensitive?

Accepted Answer

Gallamine

Answer

Atracurium

Answer

Scoline

Answer

Decamethonium

Question 8

Atropine is substituted by phenylephrine to facilitate fundus examination when?

Accepted Answer

Mydriasis required without cycloplegia

Answer

Cycloplegia and mydriasis both are not required

Answer

Mydriasis and cycloplegia both required

Answer

Cycloplegia is required

Question 9

The mechanism of action of botulinum toxin A is best described by:

Accepted Answer

Presynaptic blockade of acetylcholine release

Answer

Slowing of myelinated nerve fiber transmission

Answer

Postsynaptic receptor blockade

Answer

Acetylcholinesterase inhibition

Question 10

Which of the following non-depolarising muscle relaxant is excreted maximally through the kidney?

Accepted Answer

Gallamine

Answer

Rocuronium

Answer

Vecuronium

Answer

Pancuronium

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?